⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 4, 2024

Supplementary Figure S4 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation

Lily L. Nguyen Zachary L. Watson Raquel Ortega Elizabeth R. Woodruff Kimberly R. Jordan Ritsuko Iwanaga Tomomi M. Yamamoto Courtney A. Bailey Francis To Abigail D. Jeong Saketh R. Guntupalli Kian Behbakht Veronica Gibaja Nausica Arnoult Alexis Cocozaki Edward B. Chuong Benjamin G. Bitler

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S4 shows the in vivo model of HGS2 olaparib-resistant cells at day 0 and day 14 of treatment. It also shows mouse weight over the course of the treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nguyen et al. (2024) studied this question.

synapsesocial.com/papers/68e59691b6db643587531453 https://doi.org/10.1158/1535-7163.26935055.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024
2Supplementary Figure S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024
3Supplementary Figure S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024 · 1 citations
4Supplementary Figure S3 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024
5Supplementary Figure S3 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024

Supplementary Figure S6 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024
Supplementary Figure S6 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024
Supplementary Figure S7 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024